Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Keenova Therapeutics Plc's Business Segments
Keenova Therapeutics Plc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of FY
Reportable Segments
12
Largest Segment
Single Reportable
Total Revenue
$ 468
Regions Reported
-
Revenue Share by Reportable Segment - FY
- Single Reportable0%
- Rebates and Chargebacks41.7%
- Acthar Gel36.2%
- Xiaflex28.7%
- Other Products16.8%
- INOmax12.6%
- Amitiza4.5%
- Product Returns1.4%
- License Revenue1.3%
- Other Sales Deductions1%
- Transferred at Point in Time0%
- Transferred over Time0%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Single Reportable | $ 986 | - |
| Rebates and Chargebacks | $ 195 | 41.7% |
| Acthar Gel | $ 170 | 36.2% |
9 more segments available
Sign in to unlock the full Keenova Therapeutics Plc dataset.
Revenue by Product & Service Category - FY
- Acthar Gel36.2%
- Xiaflex28.7%
- Other Products16.8%
- INOmax12.6%
- Amitiza4.5%
- License1.3%
Revenue by Product & Service Category - FY
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| Acthar Gel | $ 170 | 36.2% |
| Xiaflex | $ 134 | 28.7% |
| Other Products | $ 79 | 16.8% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
3 more categories available
Sign in to unlock the full Keenova Therapeutics Plc dataset.
Annual Results
Revenue Share by Reportable Segment - FY
- Single Reportable0%
- Rebates and Chargebacks41.7%
- Acthar Gel36.2%
- Xiaflex28.7%
- Other Products16.8%
- INOmax12.6%
- Amitiza4.5%
- Product Returns1.4%
- License Revenue1.3%
- Other Sales Deductions1%
- Transferred at Point in Time0%
- Transferred over Time0%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Single Reportable | $ 986 | - |
| Rebates and Chargebacks | $ 195 | 41.7% |
| Acthar Gel | $ 170 | 36.2% |
9 more segments available
Sign in to unlock the full Keenova Therapeutics Plc dataset.
Description of Keenova Therapeutics Plc
Mallinckrodt Plc is a specialty pharmaceutical company that develops and manufactures a wide range of medical products used in the treatment of rare and critical diseases.
The company was founded in 1867 and is headquartered in Dublin, Ireland, with its primary commercial offices located in the United States. With a rich history of over 150 years, Mallinckrodt has become a leading provider of medical products and services in the healthcare industry, serving millions of patients worldwide.
The company's pharmaceutical products cover a range of areas, including pain management, autoimmune and rare diseases, respiratory disorders, and central nervous system disorders. Mallinckrodt is known for producing specialty drugs such as Acthar Gel, a drug used in the treatment of autoimmune disorders, and Ofirmev, an intravenous acetaminophen injection used for pain management in hospitals.
In addition to pharmaceutical products, Mallinckrodt also produces medical devices and diagnostics tools. The company's medical devices line includes products such as surgical instruments, single-use catheters, and implantable devices for spine and orthopedics. Its diagnostics business offers various imaging agents and injectable dyes used in radiology and cardiology procedures.
Mallinckrodt's operations span over 40 countries, with manufacturing facilities located in the Americas, Europe, and Asia. The company employs over 4,500 people and maintains strong partnerships with healthcare providers and researchers.
Mallinckrodt has a strong commitment to social responsibility and sustainability. The company has implemented green initiatives to reduce its environmental footprint, such as carbon emissions reduction targets, waste diversion programs, and water conservation efforts. Furthermore, the company supports various community outreach programs, including those focused on education, health, and the environment.
Overall, Mallinckrodt is a reputable and innovative pharmaceutical company known for its high-quality products and commitment to improving patient care. Its dedication to social responsibility and sustainability has also garnered the company a positive reputation in the healthcare industry.
The company was founded in 1867 and is headquartered in Dublin, Ireland, with its primary commercial offices located in the United States. With a rich history of over 150 years, Mallinckrodt has become a leading provider of medical products and services in the healthcare industry, serving millions of patients worldwide.
The company's pharmaceutical products cover a range of areas, including pain management, autoimmune and rare diseases, respiratory disorders, and central nervous system disorders. Mallinckrodt is known for producing specialty drugs such as Acthar Gel, a drug used in the treatment of autoimmune disorders, and Ofirmev, an intravenous acetaminophen injection used for pain management in hospitals.
In addition to pharmaceutical products, Mallinckrodt also produces medical devices and diagnostics tools. The company's medical devices line includes products such as surgical instruments, single-use catheters, and implantable devices for spine and orthopedics. Its diagnostics business offers various imaging agents and injectable dyes used in radiology and cardiology procedures.
Mallinckrodt's operations span over 40 countries, with manufacturing facilities located in the Americas, Europe, and Asia. The company employs over 4,500 people and maintains strong partnerships with healthcare providers and researchers.
Mallinckrodt has a strong commitment to social responsibility and sustainability. The company has implemented green initiatives to reduce its environmental footprint, such as carbon emissions reduction targets, waste diversion programs, and water conservation efforts. Furthermore, the company supports various community outreach programs, including those focused on education, health, and the environment.
Overall, Mallinckrodt is a reputable and innovative pharmaceutical company known for its high-quality products and commitment to improving patient care. Its dedication to social responsibility and sustainability has also garnered the company a positive reputation in the healthcare industry.
Mallinckrodt Plc is a prominent global specialty pharmaceutical company that focuses on providing a diverse array of segments, products, and services tailored to meet the needs of healthcare providers and patients alike. With an emphasis on specialty medicines, the company plays a critical role in therapeutic areas requiring advanced treatment options.
Segments:
1. Specialty Brands:
Mallinckrodts specialty brands focus on high-value prescription medications that target complex medical conditions across various therapeutic areas. This segment encompasses pharmaceuticals used in:
- Pain Management: Innovative medications that help patients manage acute and chronic pain, often in the context of post-operative recovery or for those with debilitating conditions.
- Rheumatology: Treatments aimed at conditions such as rheumatoid arthritis and sarcoidosis, catering to patients who require specialized therapies to manage immune-mediated inflammatory responses.
- Neurology: Medications that address neurological disorders, offering vital solutions for patients with conditions like multiple sclerosis.
- Gastroenterology: Products designed to treat various gastrointestinal diseases and disorders, including those that affect digestion and absorption.
2. Specialty Generics:
This segment focuses on generic drugs that have complex formulations or are not widely produced by other generic manufacturers. Mallinckrodt is committed to providing affordable access to critical therapeutic options for patients, particularly in areas with limited market competition. These products may include formulations that mimic innovative therapies in existences, ensuring that patients who require these medications have access at reasonable costs.
3. Nuclear Imaging:
Mallinckrodt offers a robust portfolio of radiopharmaceuticals utilized in diagnostic imaging. This segment features products designed for various types of imaging tests, including:
- Diagnostic Agents: Radiopharmaceuticals that help visualize organ function and anatomy, essential for accurate diagnosis and treatment planning across a wide spectrum of diseases.
- Therapeutic Products: Certain agents not only serve diagnostic purposes but also provide therapeutic benefits, especially in treating malignant conditions or localized diseases.
Products:
1. Acthar Gel:
This proprietary medication is a unique formulation of adrenocorticotropic hormone (ACTH), used for treating a range of conditions including multiple sclerosis, rheumatoid arthritis, lupus, and specific cases of infantile spasms. Its utility in immunomodulation and inflammation management makes it a cornerstone product in Mallinckrodts portfolio.
2. Ofirmev:
A parenteral formulation of acetaminophen intended for use in hospitals, particularly following surgical procedures or in patients who require effective pain relief without the need for opioid medications. Ofirmev provides a critical alternative for pain management protocols.
3. Therakos:
A sophisticated medical device utilized in extracorporeal photopheresis, a treatment method that modifies the immune system to benefit patients with certain hematological malignancies and those undergoing organ transplants. The Therakos system represents an innovative approach to treating complex conditions relying on immunotherapy techniques.
4. Sucraid:
This enzyme replacement therapy specifically addresses sucrase-isomaltase deficiency in patients, allowing them to digest sugars effectively. Sucraid is essential for individuals who experience malabsorption due to this genetic disorder, enhancing their quality of life.
Services:
1. Patient Support Programs:
Mallinckrodt provides comprehensive support services to help patients navigate their treatment journeys. These programs often include educational initiatives, financial assistance, and nurse-led support, ensuring patients and their caregivers have the resources needed to manage their health effectively.
2. Medical Education:
The company prioritizes the education of healthcare providers to ensure that they are well-informed about the safe and effective use of Mallinckrodts products. This includes providing training, workshops, and educational materials that enhance practitioners’ understanding and application of the therapies in clinical practice.
3. Research and Development:
A significant focus for Mallinckrodt is its commitment to research and development aimed at advancing healthcare innovation. The company invests heavily in discovering new therapies, improving existing products, and fostering scientific advancements that lead to better patient outcomes across its therapeutic areas.
In summary, Mallinckrodt Plc is dedicated to advancing healthcare through its specialized pharmaceutical offerings that span several therapeutic areas, alongside a commitment to providing substantial patient and healthcare provider support. Its integrated approach through specialized brands, generics, and nuclear imaging products positions it as a key player in the specialty pharmaceutical landscape. Through constant innovation and emphasis on education and support services, Mallinckrodt plays a vital role in enhancing the quality of life for patients worldwide.
Segments:
1. Specialty Brands:
Mallinckrodts specialty brands focus on high-value prescription medications that target complex medical conditions across various therapeutic areas. This segment encompasses pharmaceuticals used in:
- Pain Management: Innovative medications that help patients manage acute and chronic pain, often in the context of post-operative recovery or for those with debilitating conditions.
- Rheumatology: Treatments aimed at conditions such as rheumatoid arthritis and sarcoidosis, catering to patients who require specialized therapies to manage immune-mediated inflammatory responses.
- Neurology: Medications that address neurological disorders, offering vital solutions for patients with conditions like multiple sclerosis.
- Gastroenterology: Products designed to treat various gastrointestinal diseases and disorders, including those that affect digestion and absorption.
2. Specialty Generics:
This segment focuses on generic drugs that have complex formulations or are not widely produced by other generic manufacturers. Mallinckrodt is committed to providing affordable access to critical therapeutic options for patients, particularly in areas with limited market competition. These products may include formulations that mimic innovative therapies in existences, ensuring that patients who require these medications have access at reasonable costs.
3. Nuclear Imaging:
Mallinckrodt offers a robust portfolio of radiopharmaceuticals utilized in diagnostic imaging. This segment features products designed for various types of imaging tests, including:
- Diagnostic Agents: Radiopharmaceuticals that help visualize organ function and anatomy, essential for accurate diagnosis and treatment planning across a wide spectrum of diseases.
- Therapeutic Products: Certain agents not only serve diagnostic purposes but also provide therapeutic benefits, especially in treating malignant conditions or localized diseases.
Products:
1. Acthar Gel:
This proprietary medication is a unique formulation of adrenocorticotropic hormone (ACTH), used for treating a range of conditions including multiple sclerosis, rheumatoid arthritis, lupus, and specific cases of infantile spasms. Its utility in immunomodulation and inflammation management makes it a cornerstone product in Mallinckrodts portfolio.
2. Ofirmev:
A parenteral formulation of acetaminophen intended for use in hospitals, particularly following surgical procedures or in patients who require effective pain relief without the need for opioid medications. Ofirmev provides a critical alternative for pain management protocols.
3. Therakos:
A sophisticated medical device utilized in extracorporeal photopheresis, a treatment method that modifies the immune system to benefit patients with certain hematological malignancies and those undergoing organ transplants. The Therakos system represents an innovative approach to treating complex conditions relying on immunotherapy techniques.
4. Sucraid:
This enzyme replacement therapy specifically addresses sucrase-isomaltase deficiency in patients, allowing them to digest sugars effectively. Sucraid is essential for individuals who experience malabsorption due to this genetic disorder, enhancing their quality of life.
Services:
1. Patient Support Programs:
Mallinckrodt provides comprehensive support services to help patients navigate their treatment journeys. These programs often include educational initiatives, financial assistance, and nurse-led support, ensuring patients and their caregivers have the resources needed to manage their health effectively.
2. Medical Education:
The company prioritizes the education of healthcare providers to ensure that they are well-informed about the safe and effective use of Mallinckrodts products. This includes providing training, workshops, and educational materials that enhance practitioners’ understanding and application of the therapies in clinical practice.
3. Research and Development:
A significant focus for Mallinckrodt is its commitment to research and development aimed at advancing healthcare innovation. The company invests heavily in discovering new therapies, improving existing products, and fostering scientific advancements that lead to better patient outcomes across its therapeutic areas.
In summary, Mallinckrodt Plc is dedicated to advancing healthcare through its specialized pharmaceutical offerings that span several therapeutic areas, alongside a commitment to providing substantial patient and healthcare provider support. Its integrated approach through specialized brands, generics, and nuclear imaging products positions it as a key player in the specialty pharmaceutical landscape. Through constant innovation and emphasis on education and support services, Mallinckrodt plays a vital role in enhancing the quality of life for patients worldwide.
